Cliftonlarsonallen Wealth Advisors LLC Sells 2,823 Shares of Pfizer Inc. (NYSE:PFE)

Cliftonlarsonallen Wealth Advisors LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 16.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,663 shares of the biopharmaceutical company’s stock after selling 2,823 shares during the quarter. Cliftonlarsonallen Wealth Advisors LLC’s holdings in Pfizer were worth $389,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PFE. Citizens Financial Group Inc. RI lifted its holdings in Pfizer by 63.5% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 200,310 shares of the biopharmaceutical company’s stock worth $5,605,000 after buying an additional 77,780 shares during the period. Wulff Hansen & CO. lifted its stake in shares of Pfizer by 2,698.0% in the second quarter. Wulff Hansen & CO. now owns 269,000 shares of the biopharmaceutical company’s stock worth $7,527,000 after acquiring an additional 259,386 shares during the period. Lmcg Investments LLC boosted its holdings in Pfizer by 1.1% in the second quarter. Lmcg Investments LLC now owns 51,777 shares of the biopharmaceutical company’s stock valued at $1,449,000 after acquiring an additional 543 shares during the last quarter. Excalibur Management Corp increased its position in Pfizer by 1.9% during the 2nd quarter. Excalibur Management Corp now owns 164,336 shares of the biopharmaceutical company’s stock valued at $4,598,000 after purchasing an additional 3,090 shares during the period. Finally, Moors & Cabot Inc. raised its holdings in Pfizer by 18.7% during the 2nd quarter. Moors & Cabot Inc. now owns 451,182 shares of the biopharmaceutical company’s stock worth $12,624,000 after purchasing an additional 71,082 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Stock Performance

NYSE:PFE traded up $0.18 during trading hours on Wednesday, reaching $26.59. The stock had a trading volume of 1,870,942 shares, compared to its average volume of 29,812,969. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day simple moving average of $26.13 and a 200 day simple moving average of $28.03. The stock has a market cap of $150.69 billion, a P/E ratio of 35.93, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.47%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.